An analysis of GLP-1 receptor antagonists versus standard diabetes therapies or placebo revealed significant reductions in CRP, TNFα, and malondialdehyde, and significant increases in adiponectin [83]. The gene discussed is TNF; the disease is diabetes mellitus.